

### A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

**NAME** : Mrs. VEENA JAIN

**AGE/ GENDER** : 62 YRS/FEMALE **PATIENT ID** : 1673565

**COLLECTED BY** REG. NO./LAB NO. : 122411160019

REFERRED BY **REGISTRATION DATE** : 16/Nov/2024 12:56 PM BARCODE NO. : 12505689 **COLLECTION DATE** : 16/Nov/2024 01:01PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 16/Nov/2024 01:40PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Value** Unit **Biological Reference interval Test Name** 

#### **CLINICAL CHEMISTRY/BIOCHEMISTRY**

**LIPID PROFILE: BASIC** 

	LII ID I ROTILI	L. Drible	
CHOLESTEROL TOTAL: SERUM by CHOLESTEROL OXIDASE PAP	189.83	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR =
TRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)	141.63	mg/dL	240.0 OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0
HDL CHOLESTEROL (DIRECT): SERUM by SELECTIVE INHIBITION	51.73	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 - 60.0 HIGH HDL: > OR = 60.0
LDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY	109.77	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0
NON HDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY	138.1 <sup>H</sup>	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0
VLDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY	28.33	mg/dL	0.00 - 45.00
TOTAL LIPIDS: SERUM by CALCULATED, SPECTROPHOTOMETRY	521.29	mg/dL	350.00 - 700.00
CHOLESTEROL/HDL RATIO: SERUM	3.67	RATIO	LOW RISK: 3.30 - 4.40



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



AVERAGE RISK: 4.50 - 7.0

by CALCULATED, SPECTROPHOTOMETRY





### A PIONEER DIAGNOSTIC CENTRE

**NAME** : Mrs. VEENA JAIN

AGE/ GENDER : 62 YRS/FEMALE **PATIENT ID** : 1673565

**COLLECTED BY** REG. NO./LAB NO. : 122411160019

REFERRED BY **REGISTRATION DATE** : 16/Nov/2024 12:56 PM BARCODE NO. **COLLECTION DATE** : 16/Nov/2024 01:01PM : 12505689 CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 16/Nov/2024 01:40PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name	Value	Unit	Biological Reference interval
LDL/HDL RATIO: SERUM	9.10	RATIO	MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0
by CALCULATED, SPECTROPHOTOMETRY	2.12	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	2.74 <sup>L</sup>	RATIO	3.00 - 5.00

**INTERPRETATION:** 

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)





### A PIONEER DIAGNOSTIC CENTRE

**NAME** : Mrs. VEENA JAIN

AGE/ GENDER : 62 YRS/FEMALE **PATIENT ID** : 1673565

**COLLECTED BY** REG. NO./LAB NO. : 122411160019

REFERRED BY **REGISTRATION DATE** : 16/Nov/2024 12:40 PM BARCODE NO. : 12505689 **COLLECTION DATE** : 16/Nov/2024 12:50PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 16/Nov/2024 04:30PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Value** Unit **Biological Reference interval Test Name** 

#### **VITAMINS**

#### VITAMIN D/25 HYDROXY VITAMIN D3

VITAMIN D (25-HYDROXY VITAMIN D3): SERUM 46.7 DEFICIENCY: < 20.0 ng/mL

by CLIA (CHEMILUMINESCENCE IMMUNOASSAY) INSUFFICIENCY: 20.0 - 30.0 SUFFICIENCY: 30.0 - 100.0

**TOXICITY:** > 100.0

**INTERPRETATION:** 

DEFICIENT:	< 20	ng/mL
INSUFFICIENT:	21 - 29	ng/mL
PREFFERED RANGE:	30 - 100	ng/mL
INTOXICATION:	> 100	ng/mL

- 1. Vitamin D compounds are derived from dietary ergocalciferol (from plants, Vitamin D2), or cholecalciferol (from animals, Vitamin D3), or by conversion of 7- dihydrocholecalciferol to Vitamin D3 in the skin upon Ultraviolet exposure.
- 2.25-OH--Vitamin D represents the main body resevoir and transport form of Vitamin D and transport form of Vitamin D, being stored in adipose tissue and tightly bound by a transport protein while in circulation.
- 3. Vitamin D plays a primary role in the maintenance of calcium homeostatis. It promotes calcium absorption, renal calcium absorption and phosphate reabsorption, skeletal calcium deposition, calcium mobilization, mainly regulated by parathyroid harmone (PTH).
- 4. Severe deficiency may lead to failure to mineralize newly formed osteoid in bone, resulting in rickets in children and osteomalacia in adults. **DECREASED:**
- 1.Lack of sunshine exposure.
- 2.Inadequate intake, malabsorption (celiac disease)
- 3. Depressed Hepatic Vitamin D 25- hydroxylase activity
- 4. Secondary to advanced Liver disease
- 5. Osteoporosis and Secondary Hyperparathroidism (Mild to Moderate deficiency)
- 6.Enzyme Inducing drugs: anti-epileptic drugs like phenytoin, phenobarbital and carbamazepine, that increases Vitamin D metabolism. INCREASED:
- 1. Hypervitaminosis D is Rare, and is seen only after prolonged exposure to extremely high doses of Vitamin D. When it occurs, it can result in severe hypercalcemia and hyperphophatemia.

CAUTION: Replacement therapy in deficient individuals must be monitored by periodic assessment of Vitamin D levels in order to prevent hypervitaminosis D

NOTE:-Dark coloured individuals as compare to whites, is at higher risk of developing Vitamin D deficiency due to excess of melanin pigment which interefere with Vitamin D absorption.

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







### A PIONEER DIAGNOSTIC CENTRE

**NAME** : Mrs. VEENA JAIN

AGE/ GENDER : 62 YRS/FEMALE **PATIENT ID** : 1673565

**COLLECTED BY** REG. NO./LAB NO. : 122411160019

REFERRED BY **REGISTRATION DATE** : 16/Nov/2024 12:40 PM BARCODE NO. : 12505689 **COLLECTION DATE** : 16/Nov/2024 12:50PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 16/Nov/2024 04:31PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Value** Unit **Biological Reference interval Test Name** 

#### VITAMIN B12/COBALAMIN

VITAMIN B12/COBALAMIN: SERUM 392.01 pg/mL 200.0 - 1100.0

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

#### INTERPRETATION:-

INCREASED VITAMIN B12	DECREASED VITAMIN B12
1.Ingestion of Vitamin C	1.Pregnancy
2.Ingestion of Estrogen	2.DRUGS:Aspirin, Anti-convulsants, Colchicine
3.Ingestion of Vitamin A	3.Ethanol Igestion
4.Hepatocellular injury	4. Contraceptive Harmones
5.Myeloproliferative disorder	5.Haemodialysis 5.Haemodialysi 5.Haemodialysis 5.Haemodialysis 5.Haemodialysis 5.Haemodialysis
6.Uremia	6. Multiple Myeloma

- 1. Vitamin B12 (cobalamin) is necessary for hematopoiesis and normal neuronal function.
- 2.In humans, it is obtained only from animal proteins and requires intrinsic factor (IF) for absorption.
- 3. The body uses its vitamin B12 stores very economically, reabsorbing vitamin B12 from the ileum and returning it to the liver; very little is excreted.
- 4. Vitamin B12 deficiency may be due to lack of IF secretion by gastric mucosa (eq. gastrectomy, gastric atrophy) or intestinal malabsorption (eq. ileal resection, small intestinal diseases).
- 5. Vitamin B12 deficiency frequently causes macrocytic anemia, glossitis, peripheral neuropathy, weakness, hyperreflexia, ataxia, loss of proprioception, poor coordination, and affective behavioral changes. These manifestations may occur in any combination; many patients have the neurologic defects without macrocytic anemia.
- 6.Serum methylmalonic acid and homocysteine levels are also elevated in vitamin B12 deficiency states.
- 7. Follow-up testing for antibodies to intrinsic factor (IF) is recommended to identify this potential cause of vitamin B12 malabsorption. NOTE:A normal serum concentration of vitamin B12 does not rule out tissue deficiency of vitamin B12. The most sensitive test for vitamin B12 deficiency at the cellular level is the assay for MMA. If clinical symptoms suggest deficiency, measurement of MMA and homocysteine should be considered, even if serum vitamin B12 concentrations are normal.

\*\*\* End Of Report \*\*\*



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

